(NewsDirect)
OKYO Pharma Ltd CEO Gary Jacob tellsProactive's Stephen Gunnion that the first patient has beenscreened for the phase II trial of OK-101, a treatment for dry eyedisease (DED), marking a significant step for the company.
Jacob says the phase II trials aims to evaluate the drug'sefficacy and safety in DED patients, with top-line data expectedbefore the end of 2023. If successful, he said the phase II assessmentcould also serve as one of the two required phase III studiesnecessary for US Food & Drug Administration (FDA) approval.
Contact Details
Proactive Investors
+1347-449-0879
na-editorial@proactiveinvestors.com
Copyright (c) 2023 TheNewswire - All rights reserved.